Regeneron’s Linvoseltamab CRL Underlines Risks Of Third-Party Manufacturers

 
• By Bridget Silverman
  
fermentation
Several CRLs have been issued recently because of third-party manufacturer issues. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Manufacturing

More from Compliance